<DOC>
	<DOC>NCT01795183</DOC>
	<brief_summary>Primary Objective: To evaluate the effectiveness of amisulpride in Chinese patients with schizophrenia Secondary Objective: To evaluate the overall safety of amisulpride in Chinese patients with schizophrenia.</brief_summary>
	<brief_title>Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia</brief_title>
	<detailed_description>The study duration by subject will include a 8-week treatment period with 3 follow-up visits.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>Inclusion criteria : Satisfying International Classification of Disease10 (ICD) diagnostic criteria of schizophrenia; Positive and Negative Syndrome Scale (PANSS) total score â‰¥ 60 Exclusion criteria: Refractory schizophrenia or Patients treated with sufficient clozapine for a minimum period of 68 weeks without improvement; Participation into another clinical trial within the last month; Patients previously or currently treated with amisulpride; Patients receiving clozapine within the past 1 month or treated with longacting formulation of antipsychotic medication within the past 2 months; Patients receiving electric convulsive therapy or physical therapy within the past 1 month; Patients with coexisting severe systemic diseases; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>